PharmaMar - Full year 2017 results
PharmaMar recently reported financial results for 2017. Sales for the year were down 0.9% to €162.6m compared to 2016. Yondelis sales fell 4.1% to...
80 Views
PharmaMar - Zepsyre misses in Ovarian, SCLC still promising
PharmaMar recently announced that Zepsyre® failed to show a progression-free survival (PFS) benefit over Topotecan and pegylated liposomal...
40 Views
PharmaMar - Aplidin and Zepsyre milestones coming up
PharmaMar investors await two key events that are expected in the next few months. The European Committee for Medicinal Products for Human Use...
61 Views
Preparing for ovarian Phase III data
Data from the 443-patient Phase III CORAIL study of Zepsyre® (lurbinectedin, PM01183) in platinum-resistant ovarian cancer is expected in H217...
64 Views
We see value in self-commercialisation
At its recent R&D day in New York, PharmaMar flagged endometrial cancer as a likely fourth indication for lurbinectedin (data to be presented...
42 Views